Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,428 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prevalence and prognostic impact of allelic imbalances associated with leukemic transformation of Philadelphia chromosome-negative myeloproliferative neoplasms.
Thoennissen NH, Krug UO, Lee DH, Kawamata N, Iwanski GB, Lasho T, Weiss T, Nowak D, Koren-Michowitz M, Kato M, Sanada M, Shih LY, Nagler A, Raynaud SD, Müller-Tidow C, Mesa R, Haferlach T, Gilliland DG, Tefferi A, Ogawa S, Koeffler HP. Thoennissen NH, et al. Among authors: nagler a. Blood. 2010 Apr 8;115(14):2882-90. doi: 10.1182/blood-2009-07-235119. Epub 2010 Jan 12. Blood. 2010. PMID: 20068225 Free PMC article. Clinical Trial.
A new MALDI-TOF-based assay for monitoring JAK2 V617F mutation level in patients undergoing allogeneic stem cell transplantation (allo SCT) for classic myeloproliferative disorders (MPD).
Koren-Michowitz M, Shimoni A, Vivante A, Trakhtenbrot L, Rechavi G, Amariglio N, Loewenthal R, Nagler A, Cohen Y. Koren-Michowitz M, et al. Among authors: nagler a. Leuk Res. 2008 Mar;32(3):421-7. doi: 10.1016/j.leukres.2007.07.003. Epub 2007 Aug 14. Leuk Res. 2008. PMID: 17698191
JAK2V617F allele burden is associated with transformation to myelofibrosis.
Koren-Michowitz M, Landman J, Cohen Y, Rahimi-Levene N, Salomon O, Michael M, Amariglio N, Nagler A. Koren-Michowitz M, et al. Among authors: nagler a. Leuk Lymphoma. 2012 Nov;53(11):2210-3. doi: 10.3109/10428194.2012.682308. Epub 2012 May 21. Leuk Lymphoma. 2012. PMID: 22524513
Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
Shimoni A, Volchek Y, Koren-Michowitz M, Varda-Bloom N, Somech R, Shem-Tov N, Yerushalmi R, Nagler A. Shimoni A, et al. Among authors: nagler a. Cancer. 2015 Mar 15;121(6):863-71. doi: 10.1002/cncr.29141. Epub 2014 Nov 11. Cancer. 2015. PMID: 25387866 Free article. Clinical Trial.
Sensitive Replicate Real-Time Quantitative PCR of BCR-ABL Shows Deep Molecular Responses in Long-Term Post-Allogeneic Stem Cell Transplantation Chronic Myeloid Leukemia Patients.
Koren-Michowitz M, Shimoni A, Daraio F, Crasto F, Lorenzatti R, Volchek Y, Amariglio N, Gottardi E, Saglio G, Nagler A. Koren-Michowitz M, et al. Among authors: nagler a. Biol Blood Marrow Transplant. 2015 Oct;21(10):1852-5. doi: 10.1016/j.bbmt.2015.06.018. Epub 2015 Jul 4. Biol Blood Marrow Transplant. 2015. PMID: 26151304 Free article.
Conditioning intensity in secondary AML with prior myelodysplastic syndrome/myeloproliferative disorders: an EBMT ALWP study.
Sengsayadeth S, Gatwood KS, Boumendil A, Labopin M, Finke J, Ganser A, Stelljes M, Ehninger G, Beelen D, Niederwieser D, Blaise D, Dreger P, Mufti G, Chevallier P, Mailhol A, Gilleece MH, Gorin N, Esteve J, Ciceri F, Baron F, Schmid C, Giebel S, Mohty M, Savani BN, Nagler A. Sengsayadeth S, et al. Among authors: nagler a. Blood Adv. 2018 Aug 28;2(16):2127-2135. doi: 10.1182/bloodadvances.2018019976. Blood Adv. 2018. PMID: 30143527 Free PMC article. Clinical Trial.
1,428 results